ipatasertib + mFOLFOX6

**Ipatasertib + mFOLFOX6** is a combination therapy consisting of ipatasertib, an oral, selective, ATP-competitive small molecule inhibitor of all three isoforms of Akt (AKT1, AKT2, AKT3), and mFOLFOX6, a modified regimen of leucovorin, 5-fluorouracil (5-FU), and oxaliplatin used as chemotherapy. The regimen has been studied in solid tumors, particularly in gastric/gastroesophageal junction cancer (GC/GEJC), in the context of improving chemotherapy effectiveness by targeting the PI3K/Akt pathway, which is commonly activated and promotes chemoresistance in several cancers. While ipatasertib shows anti-tumor effects and may enhance the efficacy of mFOLFOX6 through inhibition of Akt and related pathways, clinical studies have not demonstrated significant improvement in progression-free survival in the tested populations. Both drugs are given in their standard routes: ipatasertib orally and mFOLFOX6 intravenously[1][2].

Other names

ipatasertib/mFOLFOX6ipatasertib plus mFOLFOX6